Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects

Forensic Science, Medicine, and Pathology

Volumn 7, Issue 2, 2011, Pages 162-184

  Pilgrim, J L ^a   Gerostamoulos, D ^a   Drummer, Olaf H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

CYP450 enzymes; Drug interactions; Metabolism; Pharmacogenetics; Serotonin toxicity

Indexed keywords

CYTOCHROME P450; SEROTONIN RECEPTOR AFFECTING AGENT;

DRUG DETOXIFICATION; DRUG INTERACTION; FORENSIC MEDICINE; GENETIC POLYMORPHISM; GENETICS; HUMAN; METHODOLOGY; PHARMACOGENETICS; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FORENSIC MEDICINE; HUMANS; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SEROTONIN AGENTS;

EID: 79955717089     PISSN: 1547769X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12024-010-9188-3     Document Type: Review

References (209)

1. Runciman WB, Roughead EE, Semple SJ, Adams RJ. Adverse drug events and medication errors in Australia. Int J Qual Health Care. 2003; 15(Suppl 1): i49-59.
2. Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalised patients: a meta-analysis of prospective studies. JAMA. 1998; 279: 1200-5.
3. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329: 15-9.
4. Druzgala P. A fresh approach to adverse drug reactions. Eur Pharm Rev Drug Saf. 2004: 85-8.
5. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med. 2003; 348(6): 538-49.
6. Garcia-Quetglas E, Azanza JR, Sadaba B, Munoz MJ, Gil I, Campanero MA. Pharmacokinetics of tramadol enantiomers and their respective phase i metabolites in relation to cyp2d6 phenotype. Pharmacol Res. 2007; 55(2): 122-30.
7. Kollek R, van Aken J, Feuerstein G, Schmedders M. Pharmacogenetics, adverse drug reactions and public health. Community Genet. 2006; 9(1): 50-4.
8. McKinnon RA, Evans AM. Cytochrome p450. 3. Clinically significant drug interactions. Aust J Hosp Pharm. 2000; 30(4): 146-9.
9. McKinnon RA. Cytochrome p450. 1. Multiplicity and function. Aust J Hosp Pharm. 2000; 30: 54-6.
10. McKinnon RAE. A. M. Cytochrome p450. 2. Pharmacogenetics. Aust J Hosp Pharm. 2000; 30: 102-5.
11. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003; 348(6): 529-37.
12. Brosen K. The relationship between imipramine metabolism and the sparteine oxidation polymorphism (thesis). Dan Med Bull. 1988; 35: 460-8.
13. Rutter JL. Symbiotic relationship of pharmacogenetics and drugs of abuse. AAPS J. 2006; 8(1): E174-84.
14. Shuster L. Pharmacogenetics of drugs of abuse. Ann N Y Acad Sci. 1989; 562: 56-73.
15. Wolf CR, Smith G. Pharmacogenetics. Br Med Bull. 1999; 55(2): 366-86.
16. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome p450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007; 116(3): 496-526.
17. Shelling AN, Ferguson LR. Genetic variation in human disease and a new role for copy number variants. Mutat Res. 2007; 622(1-2): 33-41.
18. Wong SH. Pharmacogenomics and variation in drug therapy report 2005. 2005.
19. Koski A. Interpretation of postmortem toxicology results: pharmacogenetics and drug-alcohol interaction. PhD Thesis. Helsinki, Finland: University of Helsinki; 2005.
20. Danielson PB. The cytochrome p450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002; 3(6): 561-97.
21. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006; 58(3): 521-90.
22. Paar WD, Frankus P, Dengler HJ. The metabolism of tramadol by human liver microsomes. Clin Investig. 1992; 70(8): 708-10.
23. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome p450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004; 199(3): 193-209.
24. Ray WA, Griffin MR, Shorr RI. Adverse drug reactions and the elderly. Health Aff (Millwood). 1990; 9(3): 114-22.
25. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000; 356(9242): 1667-71.
26. Shi R, Winecker RE, Lo SF, Schneider RJ, Kin M, Schur BC, et al. Pharmacogenomics for clinical and forensic toxicology-an adjunct for interpretation of drug toxicity. Pharmacogenomics and proteomics: enabling the practice of personalized medicine. Tertiary pharmacogenomics for clinical and forensic toxicology-an adjunct for interpretation of drug toxicity. Washington DC, USA: AACC Press; 2006.
27. Guengerich FP. Cytochrome p450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006; 8(1): E101-11.
28. Rushmore TH, Kong AN. Pharmacogenomics, regulation and signaling pathways of phase i and ii drug metabolizing enzymes. Curr Drug Metab. 2002; 3(5): 481-90.
29. Sweeney BP. Pharmacogenomics: the genetic basis for variability in drug response. Cambridge University Press: Recent advances in anaesthesia and intensive care; 2005.
30. Wester K, Jonsson AK, Spigset O, Druid H, Hagg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol. 2008; 65(4): 573-9.
31. Kaneda Y, Kawamura I, Fujii A, Ohmori T. Serotonin syndrome-'potential' role of the cyp2d6 genetic polymorphism in asians. Int J Neuropsychopharmacol. 2002; 5(1): 105-6.
32. Blanco JG, Harrison PL, Evans WE, Relling MV. Human cytochrome p450 maximal activities in pediatric versus adult liver. Drug Metab Dispos. 2000; 28(4): 379-82.
33. Anzenbacher P, Anzenbacherova E. Cytochromes p450 and metabolism of xenobiotics. Cell Mol Life Sci. 2001; 58(5-6): 737-47.
34. Daly AK. Pharmacogenetics of the cytochromes p450. Curr Top Med Chem. 2004; 4(16): 1733-44.
35. Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther. 1993; 57(2-3): 129-60.
36. Faber MS, Jetter A, Fuhr U. Assessment of cyp1a2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol. 2005; 97(3): 125-34.
37. Druid H, Holmgren P, Carlsson B, Ahlner J. Cytochrome p450 2d6 (cyp2d6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results. Forensic Sci Int. 1999; 99(1): 25-34.
38. Cascorbi I. Pharmacogenetics of cytochrome p4502d6: genetic background and clinical implication. Eur J Clin Invest. 2003; 33(Suppl 2): 17-22.
39. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of cyp2d6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002; 53(2): 111-22.
40. Stipp D. A DNA tragedy. Fortune. 2000; 142(10): 170-4, 8, 80 passim.
41. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, et al. Genetic polymorphisms of drug-metabolizing enzymes cyp2d6, cyp2c9, cyp2c19 and cyp3a5 in the Greek population. Fundam Clin Pharmacol. 2007; 21(4): 419-26.
42. Ma JD, Nafziger AN, Bertino JSJ. Genetic polymorphisms of cytochrome p450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. J Clin Pharmacol. 2004; 44(5): 447-56.
43. Miners JO, Birkett DJ. Cytochrome p4502c9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998; 45(6): 525-38.
44. Liu ZQ, Cheng ZN, Huang SL, Chen XP, Ou-Yang DS, Jiang CH, et al. Effect of the cyp2c19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. Br J Clin Pharmacol. 2001; 52(1): 96-9.
45. Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of cyp2c19. Clin Pharmacol Ther. 2001; 70(1): 42-7.
46. Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of cyp2c19. Drug Metab Dispos. 2003; 31(10): 1255-9.
47. Bramness JG, Skurtveit S, Gulliksen M, Breilid H, Steen VM, Morland J. The cyp2c19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects. Eur J Clin Pharmacol. 2005; 61(7): 499-506.
48. Keshava C, McCanlies EC, Weston A. Cyp3a4 polymorphisms-potential risk factors for breast and prostate cancer: a huge review. Am J Epidemiol. 2004; 160(9): 825-41.
49. Burk O, Wojnowski L. Cytochrome p450 3a and their regulation. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369(1): 105-24.
50. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol. 1998; 46(2): 101-10.
51. van Schaik RH, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, Lindemans J. The cyp3a4*3 allele: is it really rare? Clin Chem. 2001; 47(6): 1104-6.
52. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human cyp3a-mediated metabolism. Adv Drug Deliv Rev. 2002; 54(10): 1271-94.
53. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome p450 2d6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369(1): 23-37.
54. Flockhart DA, Rae JM. Cytochrome p450 3a pharmacogenetics: the road that needs traveled. Pharmacogenomics J. 2003; 3(1): 3-5.
55. Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol. 2000; 18(8): 1780-99.
56. Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Med. 2008; 9(3): 315-44.
57. Armstrong SC, Cozza KL, Sandson NB. Six patterns of drug-drug interactions. Psychosomatics. 2003; 44(3): 255-8.
58. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome p450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997; 44(2): 190-4.
59. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol. 2003; 17(5): 517-38.
60. Ring BJ, Eckstein JA, Gillespie JS, Binkley SN, VandenBranden M, Wrighton SA. Identification of the human cytochromes p450 responsible for in vitro formation of r- and s-norfluoxetine. J Pharmacol Exp Ther. 2001; 297(3): 1044-50.
61. Drummer OH, Odell M. The forensic pharmacology of drugs of abuse. London: Arnold; 2001.
62. Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache. 2007; 47(2): 266-9.
63. Ener RA, Meglathery SB, van Decker WA, Gallagher RM. Serotonin syndrome and other serotonergic disorders. Pain Med. 2003; 4(1): 63-74.
64. Suchowersky O, deVries JD. Interaction of fluoxetine and selegiline. Can J Psychiatry. 1990; 35(6): 571-2.
65. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol. 1997; 17(3): 208-21.
66. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005; 352(11): 1112-20.
67. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003; 96(9): 635-42.
68. Drummer OH. Postmortem toxicology of drugs of abuse. Forensic Sci Int. 2004; 142(2-3): 101-13.
69. Silins E, Copeland J, Dillon P. Qualitative review of serotonin syndrome, ecstasy (mdma) and the use of other serotonergic substances: hierarchy of risk. Aust N Z J Psychiatry. 2007; 41: 649-55.
70. Copeland J, Dillon P, Gascoigne M. Ecstasy and the concomitant use of pharmaceuticals. Addict Behav. 2006; 31(2): 367-70. doi: 10. 1016/j. addbeh. 2005. 05. 025.
71. Kam PC, Chang GW. Selective serotonin reuptake inhibitors. Pharmacology and clinical implications in anaesthesia and critical care medicine. Anaesthesia. 1997; 52(10): 982-8.
72. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(1): 85-102.
73. Mandrioli R, Forti GC, Raggi MA. Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450. Curr Drug Metab. 2006; 7(2): 127-33.
74. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000; 85(1): 11-28.
75. Rahola JG. Antidepressants: pharmacological profile and clinical consequences. Int J Psyc Clin Pract. 2001; 5(1): 19-28.
76. Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram-a review of pharmacological and clinical effects. J Psychiatry Neurosci. 2000; 25(3): 241-54.
77. Llorca PM, Brousse G, Schwan R. Escitalopram for treatment of major depressive disorder in adults. Encephale. 2005; 31(4 Pt 1): 490-501.
78. Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol. 1995; 10(Suppl 1): 15-21.
79. Baker GB, Prior TI. Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs. Ann Med. 2002; 34(7-8): 537-43.
80. Carlsson B. From achiral to chiral analysis of citalopram. Sweden: Linkoping University; 2003.
81. Kugelberg FC, Jones AW. Interpreting results of ethanol analysis in postmortem specimens: a review of the literature. Forensic Sci Int. 2007; 165(1): 10-29.
82. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (mdma, "ecstasy"). Pharmacol Rev. 2003; 55(3): 463-508.
83. Carrasco JL, Sandner C. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract. 2005; 59(12): 1428-34.
84. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005; 95(4): 434-41.
85. Harvey AT, Burke M. Comment on: the serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med. 1995; 13(5): 605-7.
86. Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med. 1994; 12(6): 642-4.
87. Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract. 2006; 60(4): 482-91. doi: 10. 1111/j. 1368-5031. 2006. 00865. x.
88. Miura M, Ohkubo T. Identification of human cytochrome p450 enzymes involved in the major metabolic pathway of fluvoxamine. Xenobiotica. 2007; 37(2): 169-79.
89. Burke WJ, Kratochvil CJ. Stereoisomers in psychiatry: the case of escitalopram. Prim Care Companion J Clin Psychiatry. 2002; 4(1): 20-4.
90. Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, Tyndale RF. Comparison of three cyp2d6 probe substrates and genotype in ghanaians, chinese and caucasians. Pharmacogenetics. 1998; 8(4): 325-33.
91. Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-a inhibitor moclobemide. Clin Pharmacokinet. 1995; 29(5): 292-332.
92. Giroud C, Horisberger B, Eap C, Augsburger M, Menetrey A, Baumann P, et al. Death following acute poisoning by moclobemide. Forensic Sci Int. 2004; 140(1): 101-7. doi: 10. 1016/j. forsciint. 2003. 10. 021.
93. Yamada M, Yasuhara H. Clinical pharmacology of Mao inhibitors: safety and future. Neurotoxicology. 2004; 25(1-2): 215-21.
94. Chan BS, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG. Serotonin syndrome resulting from drug interactions. Med J Aust. 1998; 169(10): 523-5.
95. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C. Selegiline transdermal system: an examination of the potential for cyp450-dependent pharmacokinetic interactions with 3 psychotropic medications. J Clin Pharmacol. 2007; 47(2): 146-58.
96. Taavitsainen P, Anttila M, Nyman L, Karnani H, Salonen JS, Pelkonen O. Selegiline metabolism and cytochrome p450 enzymes: in vitro study in human liver microsomes. Pharmacol Toxicol. 2000; 86(5): 215-21.
97. Yasar S, Goldberg JP, Goldberg SR. Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research. J Neural Transm Suppl. 1996; 48: 61-73.
98. Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos. 1997; 25(6): 657-62.
99. Hasegawa M, Matsubara K, Fukushima S, Maseda C, Uezono T, Kimura K. Stereoselective analyses of selegiline metabolites: possible urinary markers for selegiline therapy. Forensic Sci Int. 1999; 101(2): 95-106.
100. Toyama SC, Iacono RP. Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann Pharmacother. 1994; 28(3): 405-6.
101. Rogers JF, Nafziger AN, Bertino JSJ. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome p450-metabolized drugs. Am J Med. 2002; 113(9): 746-50.
102. Gillman K. Venlafaxine-lithium toxicity: suitability for use in the elderly. J Clin Pharm Ther. 2007; 32(5): 529-31.
103. Baker GB, Prior TI, Coutts RT. Chirality and drugs used to treat psychiatric disorders. J Psychiatry Neurosci. 2002; 27(6): 401-3.
104. Maguire KP, Burrows GD, Norman TR, Scoggins BA. Metabolism and pharmacokinetics of dothiepin. Br J Clin Pharmacol. 1981; 12(3): 405-9.
105. Williams DA, Foye WO, Lemke TL. Foye's principles of medicinal chemistry. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2002.
106. Keller T, Schneider A, Tutsch-Bauer E. Fatal intoxication due to dothiepin. Forensic Sci Int. 2000; 109(2): 159-66.
107. Heal D, Cheetham S, Martin K, Browning J, Luscombe G, Buckett R. Comparitive pharmacology of dothiepin, its metabolites, and other antidepressant drugs. Drug Dev Res. 1992; 27: 121-35.
108. Lancaster SG, Gonzalez JP. Dothiepin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1989; 38(1): 123-47.
109. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007; 151(6): 737-48.
110. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C. The n-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic cyp2c19. Pharm Res. 2002; 19(7): 1034-7.
111. Yan JH, Hubbard JW, McKay G, Midha KK. Stereoselective in vivo and in vitro studies on the metabolism of doxepin and n-desmethyldoxepin. Xenobiotica. 1997; 27(12): 1245-57.
112. Haritos VS, Ghabrial H, Ahokas JT, Ching MS. Role of cytochrome p450 2d6 (cyp2d6) in the stereospecific metabolism of e- and z-doxepin. Pharmacogenetics. 2000; 10(7): 591-603.
113. Gutierrez MA, Stimmel GL, Aiso JY. Venlafaxine: a 2003 update. Clin Ther. 2003; 25(8): 2138-54.
114. McAlpine DE, O'Kane DJ, Black JL, Mrazek DA. Cytochrome p450 2d6 genotype variation and venlafaxine dosage. Mayo Clin Proc. 2007; 82(9): 1065-8.
115. Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine MA, O'Hara G, et al. Role of cyp2d6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics. 2003; 13(1): 39-47.
116. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997; 340(2-3): 249-58.
117. Davis R, Whittington R, Bryson HM. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997; 53(4): 608-36.
118. Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol. 1999; 12(1): 7-10.
119. Rathi SS, Grover, JK, Vats, V. Nefazodone-a new anti-depressant. JIOM. 2000; 22(1and 2).
120. Marino MR, Langenbacher M, Ulderman HD. Interaction of nefazodone and fluoxetine. Clin Pharmacol Ther. 1996; 59: 180.
121. Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by cyp3a4 from human sources. Drug Metab Dispos. 1998; 26(6): 572-5.
122. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Ishida M, et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit. 1995; 17(4): 333-5.
123. Smith KL-H, F. Association of desyrel (trazodone) with drug interactions with medications that alter cyp3a4 metabolism. Canada 2004.
124. Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant st. John's wort (hypericum perforatum l.). Eur J Clin Pharmacol. 1998; 54(8): 589-94.
125. Dannawi M. Possible serotonin syndrome after combination of buspirone and St John's Wort. J Psychopharmacol. 2002; 16(4): 401.
126. Fugh-Berman A. Herb-drug interactions. Lancet. 2000; 355(9198): 134-8.
127. Kalant H. The pharmacology and toxicology of "ecstasy" (mdma) and related drugs. CMAJ. 2001; 165(7): 917-28.
128. Shannon M. Methylenedioxymethamphetamine (mdma, "ecstasy"). Pediatr Emerg Care. 2000; 16(5): 377-80.
129. Albertson TE, Derlet RW, van Hoozen BE. Methamphetamine and the expanding complications of amphetamines. West J Med. 1999; 170(4): 214-9.
130. Musshoff F. Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine. Drug Metab Rev. 2000; 32(1): 15-44.
131. Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, Sellers EM. Reduced (±)-3, 4-methylenedioxymethamphetamine ("ecstasy") metabolism with cytochrome p450 2d6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol. 2002; 63(12): 2111-9.
132. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, et al. Non-linear pharmacokinetics of mdma ('ecstasy') in humans. Br J Clin Pharmacol. 2000; 49(2): 104-9.
133. Pizarro N, Farre M, Pujadas M, Peiro AM, Roset PN, Joglar J, et al. Stereochemical analysis of 3, 4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3, 4-dihydroxymethamphetamine). Drug Metab Dispos. 2004; 32(9): 1001-7.
134. Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, Hutt AJ. Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (ecstasy) in humans. Clin Chem. 1999; 45(7): 1058-69.
135. Oesterheld JR, Armstrong SC, Cozza KL. Ecstasy: pharmacodynamic and pharmacokinetic interactions. Psychosomatics. 2004; 45(1): 84-7.
136. Dowling GP, McDonough ET III, Bost RO. 'Eve' and 'ecstasy' A. report of five deaths associated with the use of mdea and mdma. JAMA. 1987; 257(12): 1615-7.
137. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3, 4-methylenedioxymethamphetamine ("ecstasy"). Lancet. 1992; 340(8816): 384-7.
138. Dostalek M, Jurica J, Pistovcakova J, Hanesova M, Tomandl J, Linhart I, et al. Effect of methamphetamine on cytochrome p450 activity. Xenobiotica. 2007; 37(12): 1355-66.
139. Peters FT, Samyn N, Wahl M, Kraemer T, De Boeck G, Maurer HH. Concentrations and ratios of amphetamine, methamphetamine, mda, mdma, and mdea enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by gc-nici-ms. J Anal Toxicol. 2003; 27(8): 552-9.
140. Chahl LA. Opioids-mechanism of action. Aust Prescr. 1996; 19: 63-5.
141. Matthiesen T, Wohrmann T, Coogan TP, Uragg H. The experimental toxicology of tramadol: an overview. Toxicol Lett. 1998; 95(1): 63-71.
142. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004; 43(13): 879-923.
143. Lotsch J. Opioid metabolites. J Pain Symptom Manage. 2005; 29(5 Suppl): S10-24.
144. Lewis KS, Han NH. Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm. 1997; 54(6): 643-52.
145. Shipton EA. Tramadol-present and future. Anaesth Intensive Care. 2000; 28(4): 363-74.
146. Tirkkonen T, Laine K. Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Clin Pharmacol Ther. 2004; 76(6): 639-47.
147. Mehvar R, Elliott K, Parasrampuria R, Eradiri O. Stereospecific high-performance liquid chromatographic analysis of tramadol and its o-demethylated (m1) and n, o-demethylated (m5) metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 852(1-2): 152-9.
148. Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K. Paroxetine, a cytochrome p450 2d6 inhibitor, diminishes the stereoselective o-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther. 2005; 77(4): 312-23.
149. Levo A, Koski A, Ojanpera I, Vuori E, Sajantila A. Post-mortem snp analysis of cyp2d6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci Int. 2003; 135(1): 9-15.
150. Pedersen RS, Damkier P, Brosen K. Tramadol as a new probe for cytochrome p450 2d6 phenotyping: a population study. Clin Pharmacol Ther. 2005; 77(6): 458-67.
151. Michalalkas JR, Colvill JD, Coller JK, James H, Farquharson AL, Lopatko OV, Somogyi AA, White JM, editors. Comparison of tramadol metabolism in methadone and buprenorphine maintenance patients. SEAWP-RMP, ASCEPT, HBPRCA; 2007 Dec 2-6, 2007; Adelaide, Australia.
152. Mather LE, Cousins MJ. Pharmacology of opioids. Part 2. Clinical aspects. Med J Aust. 1986; 144(9): 475-81.
153. Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, et al. Paroxetine increases steady-state concentrations of (r)-methadone in cyp2d6 extensive but not poor metabolizers. J Clin Psychopharmacol. 2002; 22(2): 211-5.
154. Eap CB, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol. 1997; 17(2): 113-7.
155. Koski A, Sistonen J, Ojanpera I, Gergov M, Vuori E, Sajantila A. Cyp2d6 and cyp2c19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. Forensic Sci Int. 2006; 158(2-3): 177-83.
156. Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ, et al. Five novel natural allelic variants-951a> c, 1042g> a (d348n), 1156a> t (i386f), 1217g> a (c406y) and 1291c> t (c431y)-of the human cyp1a2 gene in a french caucasian population. Hum Mutat. 2001; 17(4): 355-6.
157. Zhou H, Josephy PD, Kim D, Guengerich FP. Functional characterization of four allelic variants of human cytochrome p450 1a2. Arch Biochem Biophys. 2004; 422(1): 23-30.
158. Bijl D. The serotonin syndrome. Neth J Med. 2004; 62: 309-14.
159. Musshoff F, Madea B. Fatality due to ingestion of tramadol alone. Forensic Sci Int. 2001; 116(2-3): 197-9.
160. Cassens S, Nickel EA, Quintel M, Neumann P. The serotonin syndrome fatal course of intoxication with citalopram and moclobemide. Anaesthesist. 2006; 55(11): 1189-96.
161. Dams R, Benijts TH, Lambert WE, van Bocxlaer JF, van Varenbergh D, van Peteghem C, et al. A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J Anal Toxicol. 2001; 25(2): 147-51.
162. Isbister GK, McGettigan P, Dawson A. A fatal case of moclobemide-citalopram intoxication. J Anal Toxicol. 2001; 25(8): 716-7.
163. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet. 1993; 342(8884): 1419.
164. Beasley CMJ, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol. 1993; 13(5): 312-20.
165. Feighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-maoi combination therapy. J Clin Psychiatry. 1990; 51(6): 222-5.
166. Jermain DM, Hughes PL, Follender AB. Potential fluoxetine-selegiline interaction. Ann Pharmacother. 1992; 26(10): 1300.
167. Bilbao Garay J, Mesa Plaza N, Castilla Castellano V, Dhimes Tejada P. Serotonin syndrome: report of a fatal case and review of the literature. Rev Clin Esp. 2002; 202(4): 209-11.
168. Joffe RT, Bakish D. Combined ssri-moclobemide treatment of psychiatric illness. J Clin Psychiatry. 1994; 55(1): 24-5.
169. Freezer A, Salem A, Irvine RJ. Effects of 3, 4-methylenedioxymethamphetamine (mdma, 'ecstasy') and para-methoxyamphetamine on striatal 5-ht when co-administered with moclobemide. Brain Res. 2005; 1041(1): 48-55.
170. Pilgrim JL, Gerostamoulos D, Drummer OH, Bollmann M. Involvement of amphetamines in sudden and unexpected death. J Forensic Sci. 2009; 54(2): 478-85.
171. Vuori E, Henry JA, Ojanpera I, Nieminen R, Savolainen T, Wahlsten P, et al. Death following ingestion of mdma (ecstasy) and moclobemide. Addiction. 2003; 98(3): 365-8.
172. Prior FH, Isbister GK, Dawson AH, Whyte IM. Serotonin toxicity with therapeutic doses of dexamphetamine and venlafaxine. Med J Aust. 2002; 176(5): 240-1.
173. Muly EC, McDonald W, Steffens D, Book S. Serotonin syndrome produced by a combination of fluoxetine and lithium. Am J Psychiatry. 1993; 150(10): 1565.
174. Noveske FG, Hahn KR, Flynn RJ. Possible toxicity of combined fluoxetine and lithium. Am J Psychiatry. 1989; 146(11): 1515.
175. Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am J Psychiatry. 1989; 146(2): 278.
176. Evans M, Marwick P. Fluvoxamine and lithium: an unusual interaction. Br J Psychiatry. 1990; 156: 286.
177. Ohman R, Spigset O. Serotonin syndrome induced by fluvoxamine-lithium interaction. Pharmacopsychiatry. 1993; 26(6): 263-4.
178. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit. 1993; 15(3): 243-6.
179. Hartter S, Arand M, Oesch F, Hiemke C. Non-competitive inhibition of clomipramine n-demethylation by fluvoxamine. Psychopharmacology (Berl). 1995; 117(2): 149-53.
180. Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry. 1992; 55(5): 412-3.
181. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. N-demethylation of amitriptyline in vitro: role of cytochrome p-450 3a (cyp3a) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther. 1995; 275(2): 592-7.
182. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R. Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. Eur J Clin Pharmacol. 1991; 40(1): 119-20.
183. Dursun SM, Mathew VM, Reveley MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet. 1993; 342(8868): 442-3.
184. Martinelli V, Bocchetta A, Palmas AM, Del Zompo M. An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol. 1993; 36(6): 615-6.
185. Kesavan S, Sobala GM. Serotonin syndrome with fluoxetine plus tramadol. J R Soc Med. 1999; 92(9): 474-5.
186. Mason BJ, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann Pharmacother. 1997; 31(2): 175-7.
187. Mahlberg R, Kunz D, Sasse J, Kirchheiner J. Serotonin syndrome with tramadol and citalopram. Am J Psychiatry. 2004; 161(6): 1129.
188. Egberts AC, ter Borgh J, Brodie-Meijer CC. Serotonin syndrome attributed to tramadol addition to paroxetine therapy. Int Clin Psychopharmacol. 1997; 12(3): 181-2.
189. Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB. Interaction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected? J Am Med Dir Assoc. 2005; 6(4): 265-9.
190. Karunatilake H, Buckley NA. Serotonin syndrome induced by fluvoxamine and oxycodone. Ann Pharmacother. 2006; 40(1): 155-7.
191. Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. Ann Pharmacother. 2004; 38(3): 411-3.
192. Ripple MG, Pestaner JP, Levine BS, Smialek JE. Lethal combination of tramadol and multiple drugs affecting serotonin. Am J Forensic Med Pathol. 2000; 21(4): 370-4.
193. Bush E, Miller C, Friedman I. A case of serotonin syndrome and mutism associated with methadone. J Palliat Med. 2006; 9(6): 1257-9.
194. Iribarne C, Dreano Y, Bardou LG, Menez JF, Berthou F. Interaction of methadone with substrates of human hepatic cytochrome p450 3a4. Toxicology. 1997; 117(1): 13-23.
195. Hamilton SP, Nunes EV, Janal M, Weber L. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict. 2000; 9(1): 63-9.
196. Reeves RR, Bullen JA. Serotonin syndrome produced by paroxetine and low-dose trazodone. Psychosomatics. 1995; 36(2): 159-60.
197. McCue RE, Joseph M. Venlafaxine- and trazodone-induced serotonin syndrome. Am J Psychiatry. 2001; 158(12): 2088-9.
198. Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother. 2002; 36(1): 67-71.
199. Munhoz RP. Serotonin syndrome induced by a combination of bupropion and ssris. Clin Neuropharmacol. 2004; 27(5): 219-22.
200. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol. 1994; 46(1): 35-9.
201. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and l-tryptophan: five case reports. Biol Psychiatry. 1986; 21(11): 1067-71.
202. Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy. 2006; 26(2): 269-76.
203. Erjavec MK, Coda BA, Nguyen Q, Donaldson G, Risler L, Shen DD. Morphine-fluoxetine interactions in healthy volunteers: analgesia and side effects. J Clin Pharmacol. 2000; 40(11): 1286-95.
204. Kung SWN. M. H. Serotonin syndrome with tramadol and dextromethorphan. Hong Kong J Emerg Med. 2007; 14(1): 48-52.
205. Gillman PK. Possible serotonin syndrome with moclobemide and pethidine. Med J Aust. 1995; 162(10): 554.
206. Starr C. Interaction between pethidine and selegiline. Lancet. 1991; 337(8740): 554.
207. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. Lancet. 1991; 337(8735): 246.
208. Emims [database on the Internet] 1996-2010. Available from: www. mims. com. au. Accessed: 2009-2010.
209. Welzen M, Uges DA. Tiaft reference blood level list of therapeutic and toxic substances [document online]: Www. Tiaft. Org. 2004.